Reviewnpj biomedical innovations2025
Exploring dopa decarboxylase as an ideal biomarker in Parkinson's disease with focus on regulatory mechanisms, cofactor influences, and metabolic implications.
Review in npj biomedical innovations, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Vitamin B6 produced by gut microbiome regulates host behavioral phenotypes through dopaminergic metabolism.Gut microbes · 2026Article
- Metallothionein and neurodegenerative diseases.Neural regeneration research · 2026Article
- TCMNet: an AI-driven strategy for optimizing traditional Chinese medicine.Chinese medicine · 2026Article
- A monoclonal antibody-based immunoassay reinforces DOPA decarboxylase in cerebrospinal fluid as a diagnostic biomarker for Parkinson's disease with potential prognostic value.Journal of Parkinson's disease · 2026Article
- ACE2: Friend or Foe in Post-COVID-19 Neurodegeneration?International journal of molecular sciences · 2025Review
- A repeatedly evolved mutation in Cryptochrome-1 of subterranean animals alters behavioral and molecular circadian rhythms.iScience · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD), the most common motor neurodegenerative disorder, lacks a reliable biomarker for early detection. Elevated dopa decarboxylase (DDC) levels show promise as a biomarker for PD, distinguishing it from other neurodegenerative diseases, such as Alzheimer's disease (AD). This perspective explores DDC's regulatory mechanisms, its specificity to PD, and the influence of cofactors like pyridoxal-5-phosphate, tyrosine, and thyroxine on its activity, addressing a critical question: why does elevated DDC not increase dopamine, serotonin, or norepinephrine levels?
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.